Abstract P6-09-03: Development of a cardiac toxicity prediction tool for HER2 (+) breast cancer patients receiving trastuzumab
Jeffrey Sulpher(BC Cancer Agency), Susan Dent(Washington Hospital), Christopher Johnson(Ottawa Hospital), Freya Crawley(University of Ottawa), George Dranitsaris(Augmentium Pharma Consulting (Canada)), Franco Dattilo(University of Ottawa), Maya Kovacs
Cited by 0
Related Papers
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
|JAMA Oncology|2016|375
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
|Canadian Journal of Cardiology|2016|234
Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients
|Canadian Journal of Cardiology|2016|173
Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
|Echo Research and Practice|2016|56